Table 3.

Univariate and multivariate logistic regression analyses for progression-free survival in non-small cell lung cancer patients treated with immune checkpoint inhibitors after propensity score matching.

Variable	Category	Univariate analysis		Multivariate analysis
		HR (95% CI)	p-value	HR (95% CI)	p-value
Age, years	⩾61 versus <61	0.78 (0.59−1.03)	0.09	0.81 (0.60−1.08)	0.16
Sex	Female versus male	1.33 (0.97−1.83)	0.07	1.35 (0.87−2.07)	0.17
Smoking history	Yes versus no	0.92 (0.69−1.22)	0.57	1.24 (0.83−1.85)	0.28
Histology	Squamous versus non-squamous	0.87 (0.64−1.17)	0.36	0.80 (0.58−1.10)	0.18
Stage	IV versus III	0.98 (0.66−1.47)	0.96	0.81 (0.52−1.24)	0.34
ECOG PS	⩾2 versus 0−1	1.12 (0.61−2.03)	0.71	1.07 (0.56−2.05)	0.82
Treatment type	Combination therapy versus monotherapy	0.75 (0.57−0.99)	<0.05	0.73 (0.54−0.99)	<0.05
Prior lines of therapy	1 line versus 2 lines versus ⩾3 lines	1.24 (1.04−1.42)	0.01	1.16 (0.9−1.42)	0.13
Brain metastasis	Yes versus no	1.70 (1.18−2.44)	<0.01	1.40 (0.95−2.05)	0.08
Baseline Hb, g/L	⩾110 versus <110	0.63 (0.47−0.83)	<0.01	0.67 (0.50−0.91)	0.01

CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; Hb, hemoglobin; HR, hazard ratio.